Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-06 | 2024-03 | -0.23 | N/A | N/A | N/A |
2024-02-26 | 2023-12 | -0.24 | -0.28 | -0.04 | -16.67% |
2023-11-02 | 2023-09 | -0.25 | -0.19 | 0.06 | 24.00% |
2023-08-03 | 2023-06 | -0.25 | -0.24 | 0.01 | 4.00% |
2023-05-03 | 2023-03 | -0.3 | -0.28 | 0.02 | 6.67% |
2023-02-21 | 2022-12 | -0.19 | -0.38 | -0.19 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | RBC Capital | Upgrade | Outperform | Outperform |
2023-09-17 | RBC Capital | Upgrade | Sector Perform | Outperform |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-08-03 | Jefferies | Upgrade | Hold | Buy |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-02 | Needham | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-13 | BARNES ALANE P | Officer | 296.02K | Stock Award(Grant) |
2023-12-13 | DOYLE ANTHONY | Chief Financial Officer | 229.93K | Stock Award(Grant) |
2023-12-13 | GAYER CHARLES K | Officer | 277.02K | Stock Award(Grant) |
2024-02-28 | HEGGIE THERESA | Director | 51.86K | Stock Award(Grant) |
2023-06-13 | HUTSON NANCY J | Director | 81.82K | Sale |
2023-06-12 | LEVIN ALAN G | Director | 37.09K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 15.50M | 109.09M | 8.18% |
2023-06-29 | Vanguard Group Inc | 15.09M | 106.23M | 7.96% |
2023-06-29 | Baker Brothers Advisors, LLC | 12.71M | 89.48M | 6.71% |
2023-06-29 | State Street Corporation | 12.26M | 86.34M | 6.47% |
2023-06-29 | Avoro Capital Advisors LLC | 12.06M | 84.87M | 6.36% |
2023-06-29 | Assenagon Asset Management S.A. | 5.33M | 37.54M | 2.81% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 8.22M | 58.41M | 4.34% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 5.86M | 41.26M | 3.09% |
2023-08-30 | iShares Russell 2000 ETF | 4.29M | 30.51M | 2.26% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 2.81M | 19.96M | 1.48% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.58M | 18.14M | 1.36% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.44M | 17.17M | 1.29% |
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
-
Should have diversified some of my funds here instead of all in on AUPH
Congrats BCRX investors -
$BCRX What was the largest intra day gain for BCRX over the past 3 yrs.?
-
-
$BCRX Man that was like going through a six hour blow job and no orgasm and I’m 78 yrs old damn
-
$BCRX Who’s gona do it keep buying you could be the one
-
$BCRX I kick it I kicked it a couple of times this morning someone else try
-
$BCRX So much for that LETS GET READY TO RUMBLE tomorrow. Good luck to all.
-
$BCRX BuggZ is to busy partying with Hunter Biden
-
$BCRX I’m going to find out if my hemorrhoids are still acting up in about 30 min. If yes hello proctologist…OUCH!
-
$BCRX Man O Manischewitz
-
$BCRX Wish I was a rich man I’d be swinging from the trees ….but I’m not I’ll just keep buying and holding mabe someday
-
$BCRX No US troops to Ukraine possibly 3-5k to other Eastern European countries let’s get it straight
-
$BCRX What are we doing just gonna hand it too um I’m doing my part 100 at a time.
-
$BCRX I get a kick out of this
-
$BCRX @Bio99 Thank you for the DD this evening but more importantly thank you for all the research and knowledge you have shared over the past 18 months +- God bless and may the wind always be at your back my friend.
-
$BCRX @STONEHOUSESCOFFEEMUG Well done!
-
$BCRX At least all my others are PINK that’s being positive
-
$BCRX I you going to state a fact you need to get straight
-
BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month Low at $4.15
news.google.com • -
BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month Low at $4.15
news.google.com • -
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month Low at $4.44
news.google.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report Third Quarter 2023 Financial Results on November 2
globenewswire.com • -
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
proactiveinvestors.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Second Quarter 2023 Financial Results on August 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst to Report First Quarter 2023 Financial Results on May 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Good Candidate For Buyout, But Not For Anything Else
seekingalpha.com • -
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
globenewswire.com • -
Pharmaceutical Stock Sinks on Sales Forecast
schaeffersresearch.com • -
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
globenewswire.com • -
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
seekingalpha.com • -
BCRX Stock Sinks as BioCryst Discontinues Drug Development
investorplace.com • -
BioCryst to discontinue development of drug
marketwatch.com • -
BioCryst to Present at JMP Securities Hematology & Oncology Summit
globenewswire.com • -
3 Biotechnology stocks under 10 dollars to buy now
thedogofwallstreet.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Third Quarter 2022 Financial Results on November 1
globenewswire.com • -
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com •